Fig. 3: Efficacy of obatoclax was enhanced by potential compounds via inhibitor combination screening.

A Fold change (1/cell viability) was measured using the CellTiter-Glo assay 72 h after treatment with compounds from the SCADS library with or without obatoclax (200 nM) in the DK-MG cell line. For each data point, the value of (1/cell viability) in the library compounds monotherapy was used to normalize the data. Fold changes larger than 2.0 are marked with red color. B Cell viability was measured using the CellTiter-Glo assay 72 h after treatment with 1 μM tunicamycin, bafilomycin A1, or PD173074 with or without 100 nM obatoclax in the Onda7, YH-13, and DK-MG cell lines (n = 6). ****P < 0.0001.